PharVision Advisers’s Enact Holdings ACT Stock Holding History

PharVision Advisers’s Portfolio ACT Stock Details ACT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,649	Closed	-$248K	–	266
2024 Q4	$248K	Buy	+7,649	New	+$265K	0.21%	228

Other funds holding ACT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GCM

Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

PharVision Advisers's ACT Position: Q1 2025 in Review

PharVision Advisers sold out of Enact Holdings (ACT) in Q1 2025, closing a stake of 7,649 shares — an estimated $248K sold.

PharVision Advisers first reported a position in ACT in Q4 2024 and held it in 1 quarter. The position peaked at $248K in Q4 2024. 226 funds tracked by Wall St. Rank hold ACT as of Q1 2025.

PharVision Advisers reported no remaining Enact Holdings position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 7,649 Enact Holdings shares in Q1 2025, an estimated $248K.
PharVision Advisers first reported a position in Enact Holdings in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Enact Holdings position peaked at $248K in Q4 2024.
226 funds tracked by Wall St. Rank held Enact Holdings as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.